Patrick Kilbride Image

Patrick Kilbride

Policy Advisor, Public Speaker & Corporate Trainer

Kilbride Public Affairs

Patrick Kilbride is a public policy expert specializing in innovation, intellectual property, and international trade at Kilbride Public Affairs.

Patrick was previously senior vice president of the Global Innovation Policy Center (GIPC), Executive Vice President, Association of American Chambers of Commerce in Latin America (AACCLA), and founder of the Coalition for the Rule of Law in Global Markets at the U.S. Chamber of Commerce.

Prior to joining the U.S. Chamber, Kilbride was appointed to serve in the Bush administration as deputy assistant U.S. Trade Representative (USTR) for Intergovernmental Affairs & Public Liaison. At USTR, Kilbride worked with state and local officials, business organizations, and non-governmental organizations to advance the President’s trade policy agenda; he served as USTR liaison to the network of industry trade advisory committees (ITACs), as well as the President’s Export Council; and, he was part of a White House-led, inter-agency team that coordinated efforts to secure congressional approval of pending U.S. free trade agreements.

Kilbride began his career in global economic policy as an international trade specialist with the law firm of LeBoeuf, Lamb, Greene & MacRae.

Recent Articles by Patrick Kilbride

Only Congressional Patent Reform Can Restore Constitutional Rights

Encouraged and abetted by free riders who would benefit unfairly from others’ work, well-intentioned lawmakers and judicial activists have compromised the U.S. patent system, threatening America’s prosperity and national security. But we have the chance to reverse this trend by supporting two bills that will be debated this week in the Senate Judiciary Committee.

Debunked: USPTO Findings Should End False Pharma Patent Narratives

One of the more interesting public policy reads of 2024 comes from the U.S. Patent and Trademark Office (USPTO), whose “Drug Patent and Exclusivity Study” effectively debunks the false narratives and bogus statistics that have been levied against pharmaceutical patents with significant effect in recent years. The inescapable takeaway from the USPTO study is that activists have manipulated data to inflate the effects of patents and other exclusive rights on competition.

Let’s Get Visual: Using AI to Convey the Significance of Injunctive Relief

We’ve all heard that a picture is worth 1,000 words. Political affairs firm Neptune Ops suggests taking that truism to its logical conclusion: “[R]esearch shows that the human brain processes visual information 60,000 times faster than text. … So, when Professor Adam Mossoff, a respected expert on intellectual property policy matters, posted on LinkedIn about the historical treatment of injunctive relief for IP infringement in the United States, I was inspired to take up Neptune’s challenge to try to deliver a compelling message about the significance—and availability—of injunctive relief mainly via AI-generated images.

A Healthy Patent Family Is A Tree That Continues to Bear Fruit

When the Senate Judiciary Committee convened on May 21 for a hearing on Competition in the Prescription Drug Market, Senators were besieged with an array of tired and superficial arguments against patents for biopharmaceutical innovation. The main premise seemed to be that holding more than a single patent for a single product must be anti-competitive. These arguments fly in the face of technological, economic, and legal reality, where patents cover inventions and discoveries rather than products. The ubiquitous mobile phone by one estimate contains 250,000 patented inventions, each adding a unique capability or solving a technical problem, which collectively enable the whole phone to work as intended.

Why IP Rights Expire and Why They Must Be Strong While They Last

Imagine building a house and by law, 20 years from completion, all ownership rights to the asset expired permanently whether retained by the original owner or obtained through purchase. Notwithstanding rising real estate values, the ability to reap the benefit of that asset’s appreciation would decrease rapidly for every year the property was owned. After 20 years, as the house passed into the public domain, you might continue to live there, but its investment or resale value would effectively become zero. This is the reality for intellectual property rights, which are time-limited by law, a condition established by the U.S. Constitution.

Upcoming Events with Patrick Kilbride

IPWatchdog LIVE 2026

March 22-24, 2026

Past Events with Patrick Kilbride

Life Sciences Masters™ 2025

October 27 - 29, 2025

IPWatchdog LIVE 2025

March 2, 2025 - March 4, 2025

Life Sciences Masters™ 2024

October 28 - 30, 2024

IPWatchdog LIVE 2024

September 29, 2024-October 1, 2024

IPWatchdog LIVE 2023

September 17-19, 2023

IPWatchdog LIVE 2022

September 11-13, 2022

IPWatchdog Virtual International IP Masters™ 2022

March 7, 2022 @ 8:30 am - March 10, 2022 @ 12:30 pm EST

IPWatchdog LIVE 2021

September 12-14, 2021

Global Patent Landscape 2018: Where to File and Why

March 22, 2018 @ 12:00 pm - 1:00 pm EDT

Global Patent Landscape: Where to File and Why

April 5, 2017 @ 12:00 pm - 1:00 pm EDT